BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 31176807)

  • 1. Towards the global elimination of cervical cancer.
    Canfell K
    Papillomavirus Res; 2019 Dec; 8():100170. PubMed ID: 31176807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
    Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
    Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
    Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
    Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDC Activities for Improving Implementation of Human Papillomavirus Vaccination, Cervical Cancer Screening, and Surveillance Worldwide.
    Senkomago V; Duran D; Loharikar A; Hyde TB; Markowitz LE; Unger ER; Saraiya M
    Emerg Infect Dis; 2017 Dec; 23(13):S101-7. PubMed ID: 29155666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
    Hall MT; Smith MA; Simms KT; Barnabas R; Murray JM; Canfell K
    Int J Cancer; 2021 Jul; 149(2):297-306. PubMed ID: 33634857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
    Poljak M
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevention of cervical cancer (II): prophylactic HPV vaccination, current knowledge, practical procedures and new issues].
    Monsonego J
    Presse Med; 2007 Apr; 36(4 Pt 2):640-66. PubMed ID: 17350792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Qualitative Study of Parental Knowledge and Perceptions of Human Papillomavirus and Cervical Cancer Prevention in Rural Central Java, Indonesia: Understanding Community Readiness for Prevention Interventions.
    Spagnoletti BRM; Bennett LR; Wahdi AE; Wilopo SA; Keenan CA
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2429-2434. PubMed ID: 31450917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases.
    Bosch FX; Tsu V; Vorsters A; Van Damme P; Kane MA
    Vaccine; 2012 Nov; 30 Suppl 5():F1-11. PubMed ID: 23199951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries.
    Campos NG; Sharma M; Clark A; Lee K; Geng F; Regan C; Kim J; Resch S
    Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():47-56. PubMed ID: 28691334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating HPV vaccination programs with enhanced cervical cancer screening and treatment, a systematic review.
    Wirtz C; Mohamed Y; Engel D; Sidibe A; Holloway M; Bloem P; Kumar S; Brotherton J; Reis V; Morgan C
    Vaccine; 2022 Mar; 40 Suppl 1():A116-A123. PubMed ID: 34863615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study.
    Xia C; Hu S; Xu X; Zhao X; Qiao Y; Broutet N; Canfell K; Hutubessy R; Zhao F
    Lancet Public Health; 2019 Sep; 4(9):e462-e472. PubMed ID: 31493843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
    Aljunid S; Zafar A; Saperi S; Amrizal M
    Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.
    Simms KT; Smith MA; Lew JB; Kitchener HC; Castle PE; Canfell K
    Int J Cancer; 2016 Dec; 139(12):2771-2780. PubMed ID: 27541596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M; Jasani B; Fiander A
    Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.